Baillie Gifford & Co. Has $6.70 Million Stake in Quanterix Co. (NASDAQ:QTRX)

Baillie Gifford & Co. trimmed its holdings in Quanterix Co. (NASDAQ:QTRX) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 629,797 shares of the company’s stock after selling 3,204 shares during the period. Baillie Gifford & Co. owned 1.63% of Quanterix worth $6,695,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in QTRX. SG Americas Securities LLC acquired a new stake in shares of Quanterix in the third quarter valued at approximately $139,000. nVerses Capital LLC bought a new stake in shares of Quanterix during the third quarter worth $60,000. abrdn plc grew its stake in shares of Quanterix by 163.6% during the third quarter. abrdn plc now owns 166,398 shares of the company’s stock worth $2,157,000 after buying an additional 103,281 shares during the last quarter. Janney Capital Management LLC grew its stake in shares of Quanterix by 33.6% during the third quarter. Janney Capital Management LLC now owns 23,553 shares of the company’s stock worth $305,000 after buying an additional 5,930 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its stake in shares of Quanterix by 0.8% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 563,247 shares of the company’s stock worth $7,300,000 after buying an additional 4,406 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, TD Cowen boosted their price objective on shares of Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Stock Down 3.7 %

QTRX stock opened at $7.75 on Wednesday. The firm has a market cap of $298.53 million, a price-to-earnings ratio of -7.31 and a beta of 1.33. Quanterix Co. has a 12-month low of $7.49 and a 12-month high of $29.70. The company’s fifty day simple moving average is $9.87 and its 200 day simple moving average is $11.70.

Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, December 23rd. The company reported ($0.22) earnings per share (EPS) for the quarter. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. Research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.